Reason for request
Key points
Favourable opinion for maintenance of reimbursement in combination with lenalidomide and dexamethasone in the treatment of adult patients with multiple myeloma who have received at least one prior treatment.
What therapeutic improvement ?
No clinical added value compared to the lenalidomide/dexamethasone combination.
Role in the care pathway ?
There is no standard treatment for the first relapse or progression of multiple myeloma. The therapeutic decision depends on age, previous treatments, the duration of the first remission, the circumstances of the relapse, the general health status of patients and their comorbidities.
Role of the medicinal product in the care pathway
NINLARO (ixazomib) in combination with lenalidomide and dexamethasone remains a therapeutic option in the treatment of patients with multiple myeloma who have received at least one prior treatment.
Clinical Benefit
Substantial |
The Committee deems that the clinical benefit of NINLARO remains substantial in the MA indication. |
Clinical Added Value
no clinical added value |
Considering :
the Committee considers that NINLARO, in combination with lenalidomide and dexamethasone, provides no clinical added value (CAV V) compared to the lenalidomide and dexamethasone combination, in patients with multiple myeloma having already received at least one treatment line. |